57 min
Phase 1 Study of Cabozantinib in Combination with Topotecan-Cyclophosphamide for Patients with Relapsed or Refractory Ewing Sarcoma or Osteosarcoma MIB Agents OsteoBites
-
- Medicine
Kevin Campbell, MD, a pediatric oncologist at Children's Mercy Kansas City and Clinical Assistant Professor of Pediatrics, University of Missouri-Kansas City School of Medicine discusses results from the Phase 1 study assessing the safety and toxicity of cabozantinib in combination with topotecan and cyclophosphamide for relapsed osteosarcoma and Ewing sarcoma.Dr. Kevin Campbell is a pediatric oncologist at Children's Mercy Kansas City and a Clinical Assistant Professor of Pediatrics at the University of Missouri-Kansas City School of Medicine. He has an interest in clinical trials relevant to children with solid tumors, with an emphasis on neuroblastoma and sarcomas. During his training at Dana-Farber Cancer Institute/Boston Children’s Hospital and now extending into his career as an attending, his research focuses on clinical outcomes for patients with high-risk or advanced solid tumors and the development and implementation of early phase clinical trials with novel agents or combinations of agents to improve outcomes.His work to advance clinical trials includes experience in multiple spheres. He has completed specific training in the writing, development and management of early phase clinical trials and currently has a phase I clinical trial open which he developed. His work also involves the analysis of biomarkers that have been incorporated into national phase II and phase III clinical trials.
Kevin Campbell, MD, a pediatric oncologist at Children's Mercy Kansas City and Clinical Assistant Professor of Pediatrics, University of Missouri-Kansas City School of Medicine discusses results from the Phase 1 study assessing the safety and toxicity of cabozantinib in combination with topotecan and cyclophosphamide for relapsed osteosarcoma and Ewing sarcoma.Dr. Kevin Campbell is a pediatric oncologist at Children's Mercy Kansas City and a Clinical Assistant Professor of Pediatrics at the University of Missouri-Kansas City School of Medicine. He has an interest in clinical trials relevant to children with solid tumors, with an emphasis on neuroblastoma and sarcomas. During his training at Dana-Farber Cancer Institute/Boston Children’s Hospital and now extending into his career as an attending, his research focuses on clinical outcomes for patients with high-risk or advanced solid tumors and the development and implementation of early phase clinical trials with novel agents or combinations of agents to improve outcomes.His work to advance clinical trials includes experience in multiple spheres. He has completed specific training in the writing, development and management of early phase clinical trials and currently has a phase I clinical trial open which he developed. His work also involves the analysis of biomarkers that have been incorporated into national phase II and phase III clinical trials.
57 min